Clinical trials play an important role in developing and evaluating potential new cancer therapies.
However, enrollment of certain populations, such as adolescents and young adults (AYAs) aged 15 to 39 years, has been a persistent challenge.
“In 2006, the National Cancer Institute Progress Review Group, in collaboration with the Livestrong Foundation, identified several areas of research with the potential to improve survival disparities in this population, and that includes expanding access to clinical trials and clinical trial enrollment,” researcher Renata Abrahão, MD,